Abstract B031: The fibrolamellar carcinoma database

Abstract Fibrolamellar Carcinoma (FLC) is a liver cancer of adolescents and young adults driven by the fusion of DNAJB1, a heat shock protein and PRKACA, the catalytic subunit of protein kinase A (PKA). It is characterized by increased PKA activity leading to widespread changes. A profile of FLC at genomics, transcriptomics, methylomics and proteomics in a multi-omic study that studied 1,412 tumor-normal paired liver samples from patients with FLC, Hepatoblastoma, Intrahepatic Cholangiocarcinoma, and Hepatocellular Carcinoma, yielded the FLC Data Base (FLC-DB). To facilitate the visualization of the multiomics, we developed a user-friendly web interface for the FLC-DB. It uses functions from the R-library OmicsKit and enables interactive exploration for non-bioinformaticians to retrieve information and generate publication-ready plots. It comprises 3 main tabs. First, Documentation, which describes the samples and datasets, the transcriptomic FLC Signature, and a reduced set of 35 genes with strong and recurrent upregulation across all samples, selected for clinical purposes. Second, the Transcriptomics tab, where users can interactively explore the distribution of gene counts across liver cancers, comparing normal samples against tumors and tumor subtypes. This has the option to directly perform Differential Expression Analysis using subsets that can be dynamically defined by the user in the web interface. Third, the Genomics tab, which allows exploration of Single Nucleotide Variants (SNV) from Whole-Genome and Whole-Exome Sequencing (WGS/WES) and download of the SNVs annotations and perform downstream analyses. This allows exploring questions such as: Is a transcript consistently upregulated across FLC studies? Are there recurrent SNVs in FLC? What gene signatures are shared between FLC and HBL? The FLC-DB web interface facilitates exploration of complex multi-omics data, broadening its access to non-bioinformatic researchers, patients and the community. It is currently available at https://fibrolamellardatabase.org/. Citation Format: Daniel F. Guevara-Diaz, David Requena, Sanford M. Simon. The fibrolamellar carcinoma database [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Fusion-Positive Cancer: From Discovery to Therapy; 2026 Jan 13-15; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86(1_Suppl):Abstract nr B031.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-01-13
DOI
https://doi.org/10.1158/1538-7445.fusionpositive26-b031
Primary Topic
Cholangiocarcinoma and Gallbladder Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract B031: The fibrolamellar carcinoma database

S SIMON, David Requena, Daniel F. Guevara-Diaz
Cancer Research
Cholangiocarcinoma and Gallbladder Cancer Studies
article

Abstract B031: The fibrolamellar carcinoma database

S SIMON, David Requena, Daniel F. Guevara-Diaz
article en

Abstract

Abstract Fibrolamellar Carcinoma (FLC) is a liver cancer of adolescents and young adults driven by the fusion of DNAJB1, a heat shock protein and PRKACA, the catalytic subunit of protein kinase A (PKA). It is characterized by increased PKA activity leading to widespread changes. A profile of FLC at genomics, transcriptomics, methylomics and proteomics in a multi-omic study that studied 1,412 tumor-normal paired liver samples from patients with FLC, Hepatoblastoma, Intrahepatic Cholangiocarcinoma, and Hepatocellular Carcinoma, yielded the FLC Data Base (FLC-DB). To facilitate the visualization of the multiomics, we developed a user-friendly web interface for the FLC-DB. It uses functions from the R-library OmicsKit and enables interactive exploration for non-bioinformaticians to retrieve information and generate publication-ready plots. It comprises 3 main tabs. First, Documentation, which describes the samples and datasets, the transcriptomic FLC Signature, and a reduced set of 35 genes with strong and recurrent upregulation across all samples, selected for clinical purposes. Second, the Transcriptomics tab, where users can interactively explore the distribution of gene counts across liver cancers, comparing normal samples against tumors and tumor subtypes. This has the option to directly perform Differential Expression Analysis using subsets that can be dynamically defined by the user in the web interface. Third, the Genomics tab, which allows exploration of Single Nucleotide Variants (SNV) from Whole-Genome and Whole-Exome Sequencing (WGS/WES) and download of the SNVs annotations and perform downstream analyses. This allows exploring questions such as: Is a transcript consistently upregulated across FLC studies? Are there recurrent SNVs in FLC? What gene signatures are shared between FLC and HBL? The FLC-DB web interface facilitates exploration of complex multi-omics data, broadening its access to non-bioinformatic researchers, patients and the community. It is currently available at https://fibrolamellardatabase.org/. Citation Format: Daniel F. Guevara-Diaz, David Requena, Sanford M. Simon. The fibrolamellar carcinoma database [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Fusion-Positive Cancer: From Discovery to Therapy; 2026 Jan 13-15; Philadelphia PA. Philadelphia (PA): AACR; Cancer Res 2026;86(1_Suppl):Abstract nr B031.

Cancer ResearchVol. 86(1_Supplement)
GeoInformation (United Kingdom) (GB), Rockefeller University (US)
Openalex Percentile: Top 89%
Cholangiocarcinoma and Gallbladder Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.